Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Sanofi
Haukeland University Hospital
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)